on November 29, 2007
Published online before print November 29, 2007, doi: 10.1161/STROKEAHA.107.493767
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on May 14, 2007
From the Departments of Neurology (J.M.-F., D.C., S.M.-R., M.M.-C., J.-L.M.-V.) and Hematology (M.B., J.F.), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. * To whom correspondence should be addressed. E-mail: jmarti{at}santpau.es.
Background and Purpose—We evaluated the association between recombinant tissue-type plasminogen activator recanalization and change in hemostatic markers. Methods—We studied 40 patients. Recanalization was measured with transcranial Doppler. We evaluated the change in markers of coagulation (fibrinogen) and fibrinolysis (thrombin activatable fibrinolysis inhibitor and Results—The analyses (2-way analysis of variance) showed that the change in the value of each marker did not depend on the vascular patency status. Conclusion—From a practical point of view, the measurement of these hemostatic markers is probably not useful for predicting recanalization.
Accepted on June 7, 2007
Change in Hemostatic Markers After Recombinant Tissue-Type Plasminogen Activator Is Not Associated With the Chance of Recanalization
Joan Martí-Fàbregas PhD*;
2-antiplasmin) in patients with ischemic stroke treated with recombinant tissue-type plasminogen activator. Samples were obtained before and 90 minutes after recombinant tissue-type plasminogen activator infusion.
Key words: cerebral ischemia • hemostasis • recanalization • reperfusion • thrombolysis